nomifensine has been researched along with Parkinson Disease in 24 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "3." | 2.64 | Nomifensine in Parkinson's disease. ( Bedard, P; Marsden, CD; Parkes, JD, 1977) |
| "These mice provide a valid model of Parkinson's disease and are a resource for the investigation of pathogenesis and therapeutics." | 1.35 | Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. ( Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C, 2009) |
| "Copper sulfate (1 m M) alone was not toxic to RCSN-3 cells, but was when combined with dopamine or with dicoumarol (95% toxicity; p < 0." | 1.31 | Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. ( Azar, CO; Bennett, LB; Caviedes, P; Caviedes, R; Dagnino-Subiabre, A; Marcelain, K; Paris, I; Segura-Aguilar, J, 2001) |
| "Post-mortem neurochemical studies in Parkinson's disease (PD) have shown that, in addition to the typical nigro-striatal dopamine denervation, there exists a concomitant neocortical monoamine fibre deafferentation (of variable severity) whose role in motor, and especially in associated cognitive and affective impairment, remains elusive." | 1.29 | PET imaging of neocortical monoaminergic terminals in Parkinson's disease. ( Allain, P; Baron, JC; Barré, L; Lechevalier, B; Marié, RM; Rioux, P, 1995) |
| "Two patients with advanced Parkinson's disease were followed for 6 months before, and 18 months after, receiving stereotaxic grafts of fetal mesencephalic tissue from aborted human fetuses." | 1.28 | Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's disease. ( Bygdeman, M; Freedman, R; Gerhardt, G; Hoffer, BJ; Leenders, KL; Olson, L; Seiger, A; Strömberg, I; Young, D; Zerbe, GO, 1992) |
| "In patients with Parkinson's disease, striatal uptake of both tracers was decreased, putamen being significantly more affected than caudate." | 1.28 | The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. ( Brooks, DJ; Frackowiak, RS; Jones, T; Leenders, KL; Marsden, CD; Perani, D; Sager, H; Salmon, EP; Tyrrell, P, 1990) |
| "11C-nomifensine and PET seems to be an auspicious method to measure the striatal dopaminergic nerve terminals of man in vivo." | 1.27 | In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. ( Antoni, G; Aquilonius, SM; Bergström, K; Eckernäs, SA; Gee, A; Hartvig, P; Leenders, KL; Lundquist, H; Rimland, A; Uhlin, J, 1987) |
| "Although the cause of Parkinson's disease is still unknown it has become clear that dopaminergic cell loss in the substantia nigra is a prominent feature of the disease." | 1.27 | Parkinson's disease and PET tracer studies. ( Leenders, KL, 1988) |
| "11C-nomifensine seems to be a valuable tool for investigating noradrenergic and dopaminergic re-uptake sites in vivo." | 1.27 | Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. ( Aquilonius, SM; Gee, AG; Hartvig, P; Långström, B; Lundqvist, H; Tedroff, J; Uhlin, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (37.50) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Salvatore, MF | 1 |
| Kasanga, EA | 1 |
| Kelley, DP | 1 |
| Venable, KE | 1 |
| McInnis, TR | 1 |
| Cantu, MA | 1 |
| Terrebonne, J | 1 |
| Lanza, K | 1 |
| Meadows, SM | 1 |
| Centner, A | 1 |
| Bishop, C | 1 |
| Ingram, DK | 1 |
| Sahin, G | 1 |
| Thompson, LH | 1 |
| Lavisse, S | 1 |
| Ozgur, M | 1 |
| Rbah-Vidal, L | 1 |
| Dollé, F | 1 |
| Hantraye, P | 1 |
| Kirik, D | 1 |
| Stopper, H | 1 |
| Schupp, N | 1 |
| Fazeli, G | 1 |
| Dietel, B | 1 |
| Queisser, N | 1 |
| Walitza, S | 1 |
| Gerlach, M | 1 |
| Li, Y | 1 |
| Liu, W | 1 |
| Oo, TF | 1 |
| Wang, L | 1 |
| Tang, Y | 1 |
| Jackson-Lewis, V | 1 |
| Zhou, C | 1 |
| Geghman, K | 1 |
| Bogdanov, M | 1 |
| Przedborski, S | 1 |
| Beal, MF | 1 |
| Burke, RE | 1 |
| Li, C | 1 |
| Lee, KH | 1 |
| Blaha, CD | 1 |
| Harris, BT | 1 |
| Cooper, S | 1 |
| Hitti, FL | 1 |
| Leiter, JC | 1 |
| Roberts, DW | 1 |
| Kim, U | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Baldassarre, M | 1 |
| Rocco, A | 1 |
| Del Roscio, S | 1 |
| D'Urso, R | 1 |
| Mearelli, S | 1 |
| Falaschi, P | 1 |
| Frajese, G | 1 |
| Park, DM | 2 |
| Findley, LJ | 2 |
| Hanks, G | 1 |
| Sandler, M | 1 |
| Marié, RM | 2 |
| Barré, L | 2 |
| Rioux, P | 1 |
| Allain, P | 1 |
| Lechevalier, B | 1 |
| Baron, JC | 2 |
| Liptrot, J | 1 |
| Holdup, D | 1 |
| Phillipson, O | 1 |
| Dupuy, B | 1 |
| Viader, F | 1 |
| Defer, G | 1 |
| Paris, I | 1 |
| Dagnino-Subiabre, A | 1 |
| Marcelain, K | 1 |
| Bennett, LB | 1 |
| Caviedes, P | 1 |
| Caviedes, R | 1 |
| Azar, CO | 1 |
| Segura-Aguilar, J | 1 |
| Teychenne, PF | 1 |
| Bedard, P | 1 |
| Parkes, JD | 1 |
| Marsden, CD | 3 |
| Hoffer, BJ | 1 |
| Leenders, KL | 6 |
| Young, D | 1 |
| Gerhardt, G | 1 |
| Zerbe, GO | 1 |
| Bygdeman, M | 1 |
| Seiger, A | 1 |
| Olson, L | 1 |
| Strömberg, I | 1 |
| Freedman, R | 1 |
| Tedroff, J | 2 |
| Aquilonius, SM | 3 |
| Hartvig, P | 3 |
| Bredberg, E | 1 |
| Bjurling, P | 1 |
| Långström, B | 2 |
| Maj, J | 1 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Sowińska, H | 1 |
| Superata, J | 1 |
| Brooks, DJ | 3 |
| Salmon, EP | 2 |
| Mathias, CJ | 1 |
| Quinn, N | 1 |
| Bannister, R | 1 |
| Frackowiak, RS | 3 |
| Tyrrell, P | 1 |
| Perani, D | 1 |
| Sager, H | 1 |
| Jones, T | 2 |
| Salmon, E | 1 |
| Turton, DR | 1 |
| Hume, SP | 1 |
| Cremer, JE | 1 |
| Bergström, K | 1 |
| Eckernäs, SA | 1 |
| Lundquist, H | 1 |
| Antoni, G | 1 |
| Gee, A | 1 |
| Rimland, A | 1 |
| Uhlin, J | 2 |
| Lundqvist, H | 1 |
| Gee, AG | 1 |
| Harvey, NS | 1 |
| Sandyk, R | 1 |
1 review available for nomifensine and Parkinson Disease
| Article | Year |
|---|---|
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female; | 1986 |
2 trials available for nomifensine and Parkinson Disease
| Article | Year |
|---|---|
Nomifensine in parkinsonism.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Isoquinolines; | 1977 |
Nomifensine in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Isoquin | 1977 |
21 other studies available for nomifensine and Parkinson Disease
| Article | Year |
|---|---|
Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake.
Topics: Animals; Caloric Restriction; Dopamine; Glial Cell Line-Derived Neurotrophic Factor; Humans; Nomifen | 2023 |
Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Benzamides; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Extracellular Space | 2014 |
Genotoxicity of the neurotransmitter dopamine in vitro.
Topics: Animals; Antioxidants; Apoptosis; Cells, Cultured; Dopamine; Humans; Micronucleus Tests; Mutagenicit | 2009 |
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial; | 2009 |
Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease.
Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; | 2006 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Age | 1980 |
Nomifensine: effect in Parkinsonian patients not receiving levodopa.
Topics: Aged; Double-Blind Method; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Nomifensine; | 1981 |
PET imaging of neocortical monoaminergic terminals in Parkinson's disease.
Topics: Aged; Carbon Radioisotopes; Cerebellum; Cerebral Cortex; Dopamine; Functional Laterality; Humans; Ma | 1995 |
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liq | 1994 |
Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease.
Topics: Adult; Aged; Caudate Nucleus; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Female; Frontal | 1999 |
Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line.
Topics: Animals; Catalase; Cell Line; Copper Sulfate; Dicumarol; Dopamine; Electron Spin Resonance Spectrosc | 2001 |
Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's disease.
Topics: Brain Tissue Transplantation; Contingent Negative Variation; Corpus Striatum; Dopamine; Female; Feta | 1992 |
Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Topics: Aged; Brain; Corpus Striatum; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; N | 1992 |
Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease.
Topics: Animals; Antipsychotic Agents; Benzophenones; Catalepsy; Catechol O-Methyltransferase; Dopamine; Dos | 1990 |
The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Topics: Adult; Aged; Atrophy; Autonomic Nervous System; Autonomic Nervous System Diseases; Brain Diseases; C | 1990 |
The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
Topics: Aged; Carbon Radioisotopes; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotope | 1990 |
A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography.
Topics: Brain; Carbon Radioisotopes; Caudate Nucleus; Cerebellum; Cerebral Cortex; Humans; Models, Theoretic | 1990 |
In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography.
Topics: Aged; Animals; Carbon Radioisotopes; Corpus Striatum; Dopamine; Female; Humans; Macaca mulatta; Male | 1987 |
Parkinson's disease and PET tracer studies.
Topics: Animals; Carbon Radioisotopes; Cerebrovascular Circulation; Corpus Striatum; Dihydroxyphenylalanine; | 1988 |
Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain; Corpus Striatum; Dopamine; Humans; Male; Middle | 1988 |
Nomifensine in advanced parkinsonism.
Topics: Aged; Humans; Levodopa; Male; Nomifensine; Parkinson Disease | 1985 |